Kedrion
Healthcare

Kedrion

  • Status Active
  • CDP Equity Start of the investment 07/05/2012
  • CDP Equity Investment size € 117 mln
  • CDP Equity Shareholding 25.1%
CDP Equity

Overview

Kedrion is one of the leading international groups (1st in Italy, 5th globally) active in the research, development, production and distribution of a wide range of plasma drug products, i.e. developed from proteins extracted from human plasma, and used to treat patients with haemophilia, primary immunodeficiencies, neuropathies, infectious diseases and other serious diseases. The group has 6 plants (4 in Italy, 1 in the United States and 1 in Hungary) and owns about 30 plasma collection centres located in the United States. Kedrion sells its products to more than 100 countries (approx. 80% of its revenue is generated abroad) and employs a total of about 2,600 employees, of which about 1,100 in Italy. The investment was made via the FSI Investimenti vehicle (77,12% owned by CDP Equity).

Rationale

CDP Equity’s investment is designed to support and accelerate Kedrion’s international development, both organically and through acquisitions. This operation has enabled the acquisition of an American division of the Johnson&Johnson Group, active in the production of RhoGAM branded drugs.